Although most studies for CLL so far were performed with CARs targeting CD19, other constructs that target different antigens were described, including CD20, CD37, and malignancy-associated B-cell receptor chains [82,83,84,85]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.